Foundation Medicine, Inc. (FMI)’s Chief Medical Officer Vincent Miller Sold 16811 shares of the Company; OGE Energy Corp. (OGE) Covered By 3 Bullish Analysts Last Week

Among 11 analysts covering OGE Energy (NYSE:OGE), 3 have Buy rating, 0 Sell and 8 Hold. Therefore 27% are positive. OGE Energy had 23 analyst reports since August 7, 2015 according to SRatingsIntel. Jefferies maintained it with “Hold” rating and $3500 target in Friday, July 21 report. The rating was downgraded by Wells Fargo on Friday, October 6 to “Market Perform”. Argus Research downgraded OGE Energy Corp. (NYSE:OGE) on Monday, April 11 to “Hold” rating. The stock of OGE Energy Corp. (NYSE:OGE) earned “Buy” rating by Bank of America on Friday, February 23. As per Friday, August 14, the company rating was maintained by Jefferies. As per Friday, August 4, the company rating was maintained by Jefferies. Jefferies maintained OGE Energy Corp. (NYSE:OGE) rating on Friday, June 9. Jefferies has “Hold” rating and $3500 target. On Thursday, July 20 the stock rating was initiated by Goldman Sachs with “Hold”. The firm has “Hold” rating given on Thursday, December 3 by Wunderlich. Bank of America initiated the stock with “Sell” rating in Tuesday, October 24 report. See OGE Energy Corp. (NYSE:OGE) latest ratings:

23/02/2018 Broker: Bank of America Rating: Buy New Target: $34.0 Upgrade
02/02/2018 Broker: UBS Rating: Neutral New Target: $33 Initiates Coverage On
18/01/2018 Broker: Bank of America Rating: Hold Upgrade
10/01/2018 Broker: Goldman Sachs Rating: Buy New Target: $38.0 Upgrade
27/12/2017 Broker: Edward Jones Old Rating: Buy New Rating: Hold Downgrade
24/10/2017 Broker: Bank of America Rating: Sell New Target: $37.0 Initiate
18/10/2017 Broker: KeyBanc Capital Markets Rating: Hold Maintain
06/10/2017 Broker: Wells Fargo Old Rating: Outperform New Rating: Market Perform Downgrade
27/09/2017 Broker: Jefferies Rating: Hold New Target: $37.0 Maintain

As discovered in a legally required document which was filled with the D.C. based-SEC on March 12, 2018, Vincent Miller, Chief Medical Officer of Foundation Medicine Inc and a well informed man, made a sale of 16,811 shares of the company for a total of $1,428,935 U.S Dollars at an average price-per-share of $85.0. He also sold 32,008 shares that are worth approx $2,460,455 USD in the last 30 days. This sell was pretty big one, so clearly it won’t go a secret. Currently, he has rights to a total of 63,322 shares or 0.17% of the company’s market capitalization (total value of the shares outstanding).

Investors sentiment increased to 1.39 in Q3 2017. Its up 0.11, from 1.28 in 2017Q2. It improved, as 11 investors sold Foundation Medicine, Inc. shares while 18 reduced holdings. 7 funds opened positions while 30 raised stakes. 9.71 million shares or 0.07% less from 9.72 million shares in 2017Q2 were reported. Rhumbline Advisers reported 16,868 shares or 0% of all its holdings. Swiss National Bank & Trust holds 0% or 24,743 shares in its portfolio. Meeder Asset has 91 shares for 0% of their portfolio. Alliancebernstein Ltd Partnership holds 672,835 shares. Gilder Gagnon Howe Ltd Liability Corp has 0.86% invested in Foundation Medicine, Inc. (NASDAQ:FMI). Employees Retirement System Of Texas has 44,000 shares. Aqr Limited Liability holds 0% or 18,608 shares in its portfolio. State Street holds 0% of its portfolio in Foundation Medicine, Inc. (NASDAQ:FMI) for 577,272 shares. Diker Mngmt Ltd Co stated it has 12,000 shares. Equitec Proprietary Markets Ltd Co reported 400 shares. Great West Life Assurance Co Can has 1,700 shares for 0% of their portfolio. Zurcher Kantonalbank (Zurich Cantonalbank) invested 0% of its portfolio in Foundation Medicine, Inc. (NASDAQ:FMI). Tiaa Cref Invest Ltd Liability Corporation stated it has 37,477 shares. Wells Fargo & Communication Mn reported 17,017 shares. Citigroup reported 9,823 shares.

Foundation Medicine, Inc. provides various molecular information products in the United States. The company has market cap of $3.02 billion. The companyÂ’s molecular information platform includes proprietary methods and algorithms to analyze specimens across various types of cancer, as well as for incorporating that information into clinical care; and offers genomic information about each patientÂ’s individual cancer, enabling physicians to optimize treatments in clinical practice and biopharmaceutical companies to develop targeted oncology therapies. It currently has negative earnings. It provides clinical products, such as FoundationOne for solid tumors; FoundationOne Heme for blood cancers, or hematologic malignancies, including leukemia, lymphoma, and myeloma, as well as sarcomas and pediatric cancers; Foundation Assay for Circulating Tumor; FoundationFocus CDxBRCA, a diagnostic assay to aid in identifying women with ovarian cancer.

Among 11 analysts covering Foundation Medicine (NASDAQ:FMI), 2 have Buy rating, 0 Sell and 9 Hold. Therefore 18% are positive. Foundation Medicine has $90.0 highest and $19 lowest target. $45.50’s average target is -44.92% below currents $82.6 stock price. Foundation Medicine had 15 analyst reports since July 30, 2015 according to SRatingsIntel. The firm has “Market Perform” rating by Wells Fargo given on Thursday, March 8. The rating was downgraded by Benchmark on Thursday, November 3 to “Hold”. As per Wednesday, September 16, the company rating was downgraded by Wells Fargo. BTIG Research downgraded Foundation Medicine, Inc. (NASDAQ:FMI) on Wednesday, November 4 to “Neutral” rating. As per Tuesday, March 7, the company rating was upgraded by Janney Capital. BTIG Research initiated the stock with “Buy” rating in Monday, September 14 report. The firm has “Neutral” rating given on Wednesday, September 21 by UBS. The stock of Foundation Medicine, Inc. (NASDAQ:FMI) has “Buy” rating given on Monday, May 15 by BTIG Research. The stock of Foundation Medicine, Inc. (NASDAQ:FMI) earned “Buy” rating by Cowen & Co on Thursday, February 15. JMP Securities downgraded the shares of FMI in report on Thursday, July 30 to “Market Perform” rating.

The stock decreased 4.12% or $3.55 during the last trading session, reaching $82.6. About 468,448 shares traded or 63.62% up from the average. Foundation Medicine, Inc. (NASDAQ:FMI) has risen 124.70% since March 12, 2017 and is uptrending. It has outperformed by 108.00% the S&P500.

Since October 2, 2017, it had 0 insider buys, and 29 selling transactions for $23.06 million activity. Cox Troy sold $1.87 million worth of stock. Ryan Jason also sold $149,504 worth of Foundation Medicine, Inc. (NASDAQ:FMI) shares. 37,288 shares were sold by Pellini Michael J, worth $2.41M on Tuesday, January 16. Shares for $211,072 were sold by Nallicheri Melanie. Shares for $2.46 million were sold by Miller Vincent A. Another trade for 23,064 shares valued at $1.62M was sold by Kafka Steven J. Another trade for 1,400 shares valued at $86,870 was made by JONES EVAN/ FA on Wednesday, December 13.

Investors sentiment increased to 1.09 in 2017 Q3. Its up 0.09, from 1 in 2017Q2. It improved, as 22 investors sold OGE Energy Corp. shares while 110 reduced holdings. 33 funds opened positions while 99 raised stakes. 123.28 million shares or 0.34% less from 123.70 million shares in 2017Q2 were reported. Tower Rech Limited Co (Trc) has 0% invested in OGE Energy Corp. (NYSE:OGE). D E Shaw And owns 0.01% invested in OGE Energy Corp. (NYSE:OGE) for 102,979 shares. Gw Henssler invested in 364,466 shares. Peapack Gladstone Fin Corp invested in 9,600 shares or 0.02% of the stock. 201,315 are owned by Barclays Public Limited. Parametric Portfolio Assocs Ltd Liability accumulated 313,245 shares. Panagora Asset Mngmt Inc holds 0% or 19,787 shares in its portfolio. Legg Mason Asset Management (Japan) invested in 0.41% or 19,300 shares. Fmr Limited Liability holds 4.84M shares or 0.02% of its portfolio. First Allied Advisory Services has 0.02% invested in OGE Energy Corp. (NYSE:OGE). Winfield Associate holds 0% or 80 shares in its portfolio. Raymond James Associate holds 367,583 shares or 0.03% of its portfolio. Hsbc Holdg Public Limited invested in 0.01% or 126,874 shares. Stifel Corp owns 24,807 shares. Bluemountain Management Lc reported 79,731 shares or 0.06% of all its holdings.

The stock increased 0.32% or $0.1 during the last trading session, reaching $31.45. About 1.44M shares traded. OGE Energy Corp. (NYSE:OGE) has risen 12.79% since March 12, 2017 and is uptrending. It has underperformed by 3.91% the S&P500.

Free Email Newsletter

Enter your email address below to get the latest news and analysts’ ratings for your stocks with our free daily email newsletter: